Partha M Das, MD
Postdoctoral Fellow
Department of Biostatistics and Bioinformatics
The Center for Genomics and Bioinformatics
Tulane University School of Public Health and Tropical Medicine
1440 Canal Street, Suite 2140
New Orleans, LA 70112
Office: (504) 988-6931 ,


Research Interests:

  • Osteoporosis and breast cancer Biomarkers
  • Global methylation changes in osteoporosis
  • Imprinted tumor suppressor genes
  • Non-coding RNA in cancer and osteoporosis
  • Companion diagnostics assay development and validation
  • Management and administration of core facilities.

I am an anatomic and clinical pathologist with research experience in the area of genomics, epigenetics and biomarker discovery.  I use a multidisciplinary systems biology approach to biomarker discovery and assay development in cancer and osteoporosis. I am trained in designing, troubleshooting and developing protocols for clinical assay development using microarray, real-time PCR, ELISA, and Luminex beads. 

Currently, I am focused on identifying novel epigenetic and long non-coding RNA markers in osteoporosis and breast cancer using next generation sequence data from multiple platforms by characterizing the epigenome, genome and transcriptome.  My ultimate is integrating different genomic technologies to efficiently move to personal genomics and medicine. I am also part of the 'Biomarker mapping to the hallmarks of cancer - therapeutic design project' of the Getting to Know Cancer undertaking (


Education and Training:

  • MD (Pathology): All India Institute of Medical Sciences. (AIIMS). New Delhi. India 1997 
  • MBBS: Jawaharlal Institute of Post-graduate Medical Education and Research. (JIPMER). Pondicherry, India - 1993 
  • Post-doctoral fellow. Frank Jones Lab. Tulane University, New Orleans, LA, 2009 - 2012
  • IPA (Ingenuity Pathway Analysis) Certified Analyst - 2009
  • Post-doctoral fellow. Dr. Robert Bast's Laboratory. MD Anderson Cancer Center, Houston, TX. – 2006 - 2009
  • Senior Research Associate, Sylvester Comprehensive Cancer Center, University of Miami – 2003 -2006
  • Chief Resident, Department of Pathology, Maulana Azad Medical College, New Delhi. India – 1999 - 2001

Honors and Awards:

  • Nominated and accepted to the American Association for the Advancement of Science – AAAS / Program for Excellence in Science – 2012.
  • Distinguished Presentation – 2010 Research Day Poster Presentation, Tulane University, New Orleans, LA
  • Tulane Cancer Center 'Matching Fund Grant' (2009-2010) – 'Role of ERBB4 as a novel tumor suppressor gene in breast cancer progression'
  • Archy Clot Award (2005) – University of Miami, Women's Cancer Association, for the study "Mechanism of methylation mediated silencing of TMS1 gene in prostate cancer"
  • Technology licensing / patents:Discovery of SIK2 as a centrosome protein. Title of Invention – The novel therapeutic target salt inducible kinase 2 (SIK2) is required for centrosome separation in mitosis. (MD Anderson office of Technology Commercialization  ref. No. MDA09-046)

Professional Memberships:

  • American Association for the Advancement of Science (AAAS)
  • Association for Molecular Pathology (AMP)
  • American Society for Investigative Pathology (ASIP)
  • American Association for Clinical Chemistry (AACC)

Major Publications:

Das PM, Thor AD, Edgerton SM, Barry SK, Chen DF, Jones FE. Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells. Oncogene. 2010 Sep 16;29 (37):5214-9. Epub 2010 Jul 5

Das PM, Bast RC Jr. Early detection of ovarian cancer. Biomark Med. 2008 Jun;2(3):291-303

Das PM, Ramachandran K, Vanwert J, Ferdinand L, Gopisetty G, Reis IM, Singal R. Methylation mediated silencing of TMS1/ASC gene in prostate cancer. Mol Cancer. 2006 Jul 18;5:28.

Das PM, Ramachandran K, vanWert J, Singal R. Chromatin immunoprecipitation assay. Biotechniques. 2004 Dec;37(6):961-9.

Das PM, Singal R. DNA methylation and cancer. J Clin Oncol. 2004 Nov 15;22(22):4632-42.

Mitra D, Das PM, Huynh FC, Jones FE Jumonji/Arid1 B (JARID1B) promotes breast tumor cell cycle progression through epigenetic repression of micro RNA let-7e. J Biol Chem. 2011 Oct 3.

Allison JG, Das PM, Ma J, Inglis FM, Jones FE The ERBB4 intracellular domain (4ICD) regulates NRG1-induced gene expression in hippocampal neurons. Neurosci Res. 2011 Jun;70(2):155-63. Epub 2011 Feb 23

Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, Jones FE. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer. 2010 Dec 20;9:317.

Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, Jones FE. Oncogenic  HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis. 2010 Dec;31(12):2049-57. Epub 2010 Sep 27.

Singal R, Das PM, Manoharan M, Reis IM, Schlesselman JJ. Polymorphisms in the DNA methyltransferase 3b gene and prostate cancer risk. Oncol Rep. 2005 Aug;14(2):569-73.

Rokicki J, Das PM, Giltnane JM, Wansbury O, Rimm DL, Howard BA, Jones FE. The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium. Mol Cancer. 2010 Jun 15;9:150.

Mandal S, Das PM, Mandal AK. Caroli's syndrome leading to splenic artery aneurysm: a rare presentation. Int J Surg Pathol. 2009 Feb;17(1):78-80. Epub 2008 May 21.

Singal R, Ferdinand L, Das PM, Reis IM, Schlesselman JJ. Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk. Int J Oncol. 2004 Nov;25(5):1465-71.

Kumar N, Das PM, Jain S, Sodhani P, Gupta S. Melanoma of the soft parts: diagnosis of metastatic and recurrent tumors by aspiration cytology. Diagn Cytopathol. 2003 Jun;28(6):295-300.



Department of Biostatistics, 1440 Canal Street, Suite 2001, New Orleans, LA 70112, 504-988-5164